Hsbc Holdings PLC Has $49.58 Million Holdings in West Pharmaceutical Services, Inc. $WST

Hsbc Holdings PLC cut its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) by 11.8% during the second quarter, Holdings Channel reports. The fund owned 138,384 shares of the medical instruments supplier’s stock after selling 18,511 shares during the period. Hsbc Holdings PLC’s holdings in West Pharmaceutical Services were worth $49,576,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in West Pharmaceutical Services in the second quarter worth $2,387,990,000. State Street Corp increased its stake in shares of West Pharmaceutical Services by 2.1% in the second quarter. State Street Corp now owns 3,271,866 shares of the medical instruments supplier’s stock valued at $715,884,000 after buying an additional 68,330 shares in the last quarter. Artisan Partners Limited Partnership raised its holdings in shares of West Pharmaceutical Services by 2.9% in the fourth quarter. Artisan Partners Limited Partnership now owns 2,850,401 shares of the medical instruments supplier’s stock valued at $784,259,000 after buying an additional 79,481 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of West Pharmaceutical Services in the second quarter valued at about $733,733,000. Finally, Generation Investment Management LLP acquired a new position in West Pharmaceutical Services during the 2nd quarter worth about $728,168,000. 93.90% of the stock is owned by institutional investors and hedge funds.

West Pharmaceutical Services Stock Performance

Shares of NYSE:WST opened at $339.90 on Tuesday. The stock has a market capitalization of $23.92 billion, a P/E ratio of 43.52, a P/E/G ratio of 2.38 and a beta of 1.14. West Pharmaceutical Services, Inc. has a 1-year low of $223.83 and a 1-year high of $386.00. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. The business has a 50-day moving average price of $350.25 and a two-hundred day moving average price of $308.00.

West Pharmaceutical Services (NYSE:WSTGet Free Report) last issued its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The company had revenue of $872.30 million for the quarter, compared to analyst estimates of $839.98 million. During the same quarter last year, the firm earned $1.84 EPS. The company’s revenue for the quarter was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Equities analysts predict that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were paid a $0.22 dividend. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 11.27%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. BNP Paribas Exane began coverage on shares of West Pharmaceutical Services in a research report on Monday, July 13th. They issued an “outperform” rating and a $447.00 price objective for the company. Stephens reiterated an “overweight” rating and set a $360.00 target price on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. Wolfe Research began coverage on shares of West Pharmaceutical Services in a research note on Monday, June 1st. They set an “outperform” rating and a $375.00 price target on the stock. Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 7th. Finally, Citigroup boosted their price objective on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, West Pharmaceutical Services has an average rating of “Moderate Buy” and a consensus price target of $368.08.

Read Our Latest Report on West Pharmaceutical Services

West Pharmaceutical Services Company Profile

(Free Report)

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.

Featured Stories

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WSTFree Report).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.